• Semaglutide

    Semaglutide is a medication that belongs to a class of drugs called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). It is primarily used for the treatment of type 2 diabetes, but it has also been studied for weight management. Here’s an explanation of how semaglutide works and an overview of the associated risks and benefits of therapy:

    Mechanism of action:

    1. Glucose regulation: Semaglutide acts by mimicking the action of a naturally occurring hormone called glucagon-like peptide-1 (GLP-1). It binds to GLP-1 receptors in various tissues, including the pancreas, which leads to increased insulin secretion. Insulin helps regulate blood sugar levels by facilitating the uptake of glucose from the bloodstream into cells.
    2. Appetite control: Semaglutide also affects the appetite-regulating centers in the brain, leading to a decrease in hunger and increased satiety (feeling of fullness). This can help in reducing food intake and promoting weight loss.


    1. Blood sugar control: Semaglutide helps lower blood sugar levels in individuals with type 2 diabetes. By enhancing insulin secretion and reducing glucagon production (a hormone that increases blood sugar levels), semaglutide can improve glycemic control and help manage diabetes.
    2. Weight loss: In addition to its glucose-lowering effects, semaglutide has been studied for its potential in weight management. Clinical trials have shown that semaglutide treatment, in combination with lifestyle modifications, can lead to significant weight loss in individuals with obesity or overweight.


    1. Gastrointestinal side effects: Semaglutide therapy can cause gastrointestinal side effects such as nausea, vomiting, diarrhea, and constipation. These side effects are usually transient and tend to improve over time. However, they can be bothersome for some individuals.
    2. Hypoglycemia: While semaglutide alone has a low risk of causing hypoglycemia (low blood sugar levels), combining it with other diabetes medications that can cause hypoglycemia may increase the risk. Individuals taking semaglutide should be cautious about hypoglycemia symptoms and closely monitor their blood sugar levels.
    3. Pancreatitis: There have been rare reports of pancreatitis (inflammation of the pancreas) associated with GLP-1 RAs, including semaglutide. While the incidence is low, individuals with a history of pancreatitis or predisposing factors should exercise caution and discuss the potential risks with their healthcare provider.
    4. Thyroid tumors: In animal studies, semaglutide has been associated with an increased risk of thyroid tumors. However, the relevance of these findings to humans is still being studied, and the clinical significance is not yet fully understood.


    It’s important to note that semaglutide therapy should be prescribed and monitored by a healthcare professional, typically an endocrinologist or healthcare provider experienced in diabetes management. They will assess an individual’s specific medical condition, consider potential risks and benefits, and guide the appropriate use of semaglutide for the management of diabetes or weight loss.


    These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any diseases.

    Month 1 Month 2 Month 3 Month 4 Month 5
    10 units 20 units 40 units 68 units 96 units
    0.25mg 0.5mg 1 mg  1.7 mg 2.4 mg

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any diseases.